- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07435298
Stimulation magnétique transcrânienne répétitive guidée pour l'acouphène chronique
Stimulation Magnétique Transcranienne Neuronaviguée Comme Traitement Adjuvant Pour Les Acouphènes Chroniques
This study is testing whether a special type of brain stimulation called neuronavigated TMS can help reduce tinnitus (ringing in the ears). 50 people with tinnitus will each receive 20 treatment sessions - 10 real treatments and 10 sham treatments in random order, with a 2-week break between them. Before starting, participants get an MRI brain scan to guide where the stimulation device is placed. Questionnaires of measuring tinnitus severity will be asked four times throughout the study to determine to check the effect of TMS on treating tinnitus.
Aperçu de l'étude
Description détaillée
This study aims to investigate the beneficial effects of neuronavigated TMS (nTMS) in alleviating tinnitus symptoms and to establish safety and tolerability of nTMS in patients with tinnitus.
50 eligible subjects will be recruited and be randomized to receive 10 sessions of daily verum nTMS followed by 10 sessions of daily sham nTMS (verum-sham), or sham nTMS followed by verum nTMS (sham-verum). There will be a 2-week break between the two types of nTMS.
MRI will be conducted before the 1st session of nTMS for the TMS navigation system.
Outcome measures include Tinnitus Handicap Inventory (THI), Tinnitus Functional Index (TFI), and Tinnitus-Visual Analogue Scale (T-VAS). All assessment will be evaluated 4 times- before the 1st nTMS session, after the 10th nTMS session, before the 11th nTMS and after the 20th nTMS session.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Singapore, Singapour
- Alexandra Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 21-80 years old;
- Subjective tinnitus severity as per Tinnitus-Visual Analogue Scale of 1/10 and above (in any domain: sound, distress, Quality of Life)
Exclusion Criteria:
- Pregnancy;
- Any metal implants inside the body that are contraindications of MRI scan;
- Cardiac pacemakers;
- Epilepsy with recurrent seizures;
- Cognitively impaired patients will be excluded;
- Claustrophobia;
- Uncontrolled medical conditions including hypertension, diabetes mellitus and unstable angina;
- Major depression and a history of psychotic disorders;
- Terminal diagnosis with life expectancy <=1 year.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: real-sham
Subjects will receive 10 sessions of real nTMS, 5 times a week for 2 weeks, followed by 10 sessions of sham nTMS, 5 times a week for 2 weeks. There will be a 2-week break between the 2 types of nTMS. |
Each session of rTMS (real or sham) consists of 1200 stimulations/day, conducted at once a day for five consecutive days (from Monday to Friday). For sham stimulation, the TMS coil will still centre on the same scalp position, but it was tilted to 90° so that scalp contact and discharging noise were similar, but the magnetic field did not reach cortical neurons at a biologically active level. The localization of the rTMS stimulation site (left Temporal Cortex) will be directed by a neuronavigation system imported with subject's MRI scan imaging to ensure the accuracy of rTMS stimulation area. |
|
Expérimental: sham-real
Subjects will receive 10 sessions of sham nTMS, 5 times a week for 2 weeks, followed by 10 sessions of real nTMS, 5 times a week for 2 weeks. There will be a 2-week break between the 2 types of nTMS. |
Each session of rTMS (real or sham) consists of 1200 stimulations/day, conducted at once a day for five consecutive days (from Monday to Friday). For sham stimulation, the TMS coil will still centre on the same scalp position, but it was tilted to 90° so that scalp contact and discharging noise were similar, but the magnetic field did not reach cortical neurons at a biologically active level. The localization of the rTMS stimulation site (left Temporal Cortex) will be directed by a neuronavigation system imported with subject's MRI scan imaging to ensure the accuracy of rTMS stimulation area. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Tinnitus Handicap Inventory (THI)
Délai: Week 0
|
THI consists of a 25 items which evaluate the subjective burden of tinnitus under a three-response system: yes (score = 4), sometimes (score = 2), or no (score = 0). THI scores of 18-36 are considered as mild tinnitus, 38-56 are considered moderate, and 58-76 are considered severe, while 78-100 are considered catastrophic. |
Week 0
|
|
Tinnitus Handicap Inventory (THI)
Délai: Week 3
|
THI consists of a 25 items which evaluate the subjective burden of tinnitus under a three-response system: yes (score = 4), sometimes (score = 2), or no (score = 0). THI scores of 18-36 are considered as mild tinnitus, 38-56 are considered moderate, and 58-76 are considered severe, while 78-100 are considered catastrophic. |
Week 3
|
|
Tinnitus Handicap Inventory (THI)
Délai: Week 6
|
THI consists of a 25 items which evaluate the subjective burden of tinnitus under a three-response system: yes (score = 4), sometimes (score = 2), or no (score = 0). THI scores of 18-36 are considered as mild tinnitus, 38-56 are considered moderate, and 58-76 are considered severe, while 78-100 are considered catastrophic. |
Week 6
|
|
Tinnitus Handicap Inventory (THI)
Délai: Week 7
|
THI consists of a 25 items which evaluate the subjective burden of tinnitus under a three-response system: yes (score = 4), sometimes (score = 2), or no (score = 0). THI scores of 18-36 are considered as mild tinnitus, 38-56 are considered moderate, and 58-76 are considered severe, while 78-100 are considered catastrophic. |
Week 7
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Tinnitus Functional Index (TFI)
Délai: Week 0
|
Tinnitus Functional Index (TFI) is a 25-item questionnaire with a 10-point Likert scale covering eight underlying dimensions: (a) intrusiveness of tinnitus; (b) sense of control; (c) cognitive interference; (d) sleep disturbance; (e) auditory difficulties; (f) interference with relaxation; (g) quality of life; and (h) emotional distress. |
Week 0
|
|
Tinnitus Functional Index (TFI)
Délai: Week 3
|
Tinnitus Functional Index (TFI) is a 25-item questionnaire with a 10-point Likert scale covering eight underlying dimensions: (a) intrusiveness of tinnitus; (b) sense of control; (c) cognitive interference; (d) sleep disturbance; (e) auditory difficulties; (f) interference with relaxation; (g) quality of life; and (h) emotional distress. |
Week 3
|
|
Tinnitus Functional Index (TFI)
Délai: Week 6
|
Tinnitus Functional Index (TFI) is a 25-item questionnaire with a 10-point Likert scale covering eight underlying dimensions: (a) intrusiveness of tinnitus; (b) sense of control; (c) cognitive interference; (d) sleep disturbance; (e) auditory difficulties; (f) interference with relaxation; (g) quality of life; and (h) emotional distress. |
Week 6
|
|
Tinnitus Functional Index (TFI)
Délai: Week 7
|
Tinnitus Functional Index (TFI) is a 25-item questionnaire with a 10-point Likert scale covering eight underlying dimensions: (a) intrusiveness of tinnitus; (b) sense of control; (c) cognitive interference; (d) sleep disturbance; (e) auditory difficulties; (f) interference with relaxation; (g) quality of life; and (h) emotional distress. |
Week 7
|
|
Tinnitus-Visual Analogue Scale (T-VAS)
Délai: Week 0
|
T-VAS is a clinical scale of the severity of tinnitus in loudness (sound), distress, and Quality of Life (QoL). The minimum value is 0 and the maximum value is 100. A higher score indicates a worse outcome, as it reflects greater perceived tinnitus loudness or severity. A score of 0 represents no tinnitus, while a score of 100 represents the worst imaginable tinnitus. |
Week 0
|
|
Tinnitus-Visual Analogue Scale (T-VAS)
Délai: Week 3
|
T-VAS is a clinical scale of the severity of tinnitus in loudness (sound), distress, and Quality of Life (QoL). The minimum value is 0 and the maximum value is 100. A higher score indicates a worse outcome, as it reflects greater perceived tinnitus loudness or severity. A score of 0 represents no tinnitus, while a score of 100 represents the worst imaginable tinnitus. |
Week 3
|
|
Tinnitus-Visual Analogue Scale (T-VAS)
Délai: Week 6
|
T-VAS is a clinical scale of the severity of tinnitus in loudness (sound), distress, and Quality of Life (QoL). The minimum value is 0 and the maximum value is 100. A higher score indicates a worse outcome, as it reflects greater perceived tinnitus loudness or severity. A score of 0 represents no tinnitus, while a score of 100 represents the worst imaginable tinnitus. |
Week 6
|
|
Tinnitus-Visual Analogue Scale (T-VAS)
Délai: Week 7
|
T-VAS is a clinical scale of the severity of tinnitus in loudness (sound), distress, and Quality of Life (QoL). The minimum value is 0 and the maximum value is 100. A higher score indicates a worse outcome, as it reflects greater perceived tinnitus loudness or severity. A score of 0 represents no tinnitus, while a score of 100 represents the worst imaginable tinnitus. |
Week 7
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Nicodemus Oey, MBBS, PhD, NUH
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2024/4506
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .